Company Overview of Novira Therapeutics, Inc.
Novira Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antiviral drugs for the treatment of chronic hepatitis B infection. It develops core and cccDNA inhibitor anti-HBV drugs. Novira Therapeutics, Inc. was formerly known as Molecmo Nanobiotechnologies, Inc. The company was incorporated in 2006 and is based in Doylestown, Pennsylvania. As of December 4, 2015, Novira Therapeutics, Inc. operates as a subsidiary of Johnson & Johnson.
3805 Old Easton Road
Doylestown, PA 18902
Founded in 2006
Key Executives for Novira Therapeutics, Inc.
Similar Private Companies By Industry
|1st Order Pharmaceuticals, Inc.||United States|
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|NYC2012, Inc.||United States|
|Tax Management Inc||United States|
|John F. Kennedy Center For The Performing Arts||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Novira Therapeutics, Inc., please visit www.noviratherapeutics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.